nach oben

Erschienen in:

01.08.2014 | Original Research

High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03_A) Influenza Vaccine

verfasst von: Karen K. Yam, Erica Gipson, Marina Klein, Sharon Walmsley, David Haase, Scott Halperin, David Scheifele, Brian J. Ward, Curtis Cooper

Erschienen in: Journal of Clinical Immunology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

More severe influenza disease and poor vaccine immunogenicity is reported in HIV-infected patients. We measured antibody avidity after influenza vaccination in HIV patients to assess vaccine efficacy.

Methods

Two dosing strategies (Group1: single dose, n = 28. Group2: single dose plus booster, n = 36) with an AS03_A-adjuvanted H1N1₂₀₀₉ pandemic influenza vaccine (Arepanrix, GSK) were assessed in HIV patients. Serum hemagglutination inhibition (HAI) titers and antibody avidity reported as an avidity index (AI) were measured at days 21 and 42 and at 6 months.

Results

Baseline HIV parameters were similar among all participants. Eighteen participants had measurable baseline HAI titers. In these subjects, AI was at ~9 at baseline and was not significantly increased by one or two vaccine doses. In those without detectable baseline antibodies, immunization induced modest antibody titers [Group1 HAI, 61 (26–144); Group2 HAI, 46 (28–76)] with high AI after one dose at day 21 [Group1 AI, 8.8 (7.3–10.7); Group2 AI, 8.9 (7.8–10.1)]. A second dose of vaccine generated significantly higher HAI titers at day 42 [Group1 HAI, 41 (18–90); Group2 HAI, 92 (64–132)] and persisted to 6 months [Group1 HAI, 9 (6–13); Group2 HAI, 19 (13–30)]. All subjects who produced detectable HAI titers after vaccination generated high antibody avidity (AI, 9–10), which persisted up to 6 months.

Conclusion

In participants initially seronegative, two doses of vaccine enabled a greater percentage of subjects to respond to the vaccine and elicited higher HAI titers. All subjects who produced detectable HAI titers also rapidly generated high AI in the short and long term. We demonstrate that high avidity antibodies can be achieved after vaccination and support a two-dose immunization strategy for HIV-positive subjects.

Nur mit Berechtigung zugänglich

Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32:1784–91.PubMedCrossRef

Radwan HM, Cheeseman SH, Lai KK, Ellison III RT. Influenza in human immunodeficiency virus-infected patients during the 1997–1998 influenza season. Clin Infect Dis. 2000;31:604–6.PubMedCrossRef

Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest. 1990;98:33–7.PubMedCrossRef

Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002;20 Suppl 5:B29–32.PubMedCrossRef

Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005;191:1442–50.PubMedCrossRef

Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med. 1987;109:545–9.PubMed

Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. 1987;316:673–6.PubMedCrossRef

Madhi SA, Dittmer S, Kuwanda L, et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS. 2013;27:369–79.PubMedCrossRef

Labriola L, Hombrouck A, Marechal C, et al. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol Dial Transplant. 2011;26:1424–8.PubMedCrossRef

10.

Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52:248–56.PubMedCrossRef

11.

McElhaney JE, Beran J, Devaster JM, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013;13:485–96.PubMedCrossRef

12.

Cooper C, Klein M, Walmsley S, et al. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials. 2012;13:23–32.PubMedCrossRef

13.

McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol. 2005;23:487–513.PubMedCrossRef

14.

Yam KK, Gupta J, Brewer A, Scheifele DW, Halperin S, Ward BJ. Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine. Clin Vaccine Immunol. 2013;20:459–67.PubMedCentralPubMedCrossRef

15.

Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4:e4384.PubMedCentralPubMedCrossRef

16.

Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52:122–7.PubMedCrossRef

17.

Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis. 2011;52:138–46.PubMedCentralPubMedCrossRef

18.

Durando P, Fenoglio D, Boschini A, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol. 2008;15:253–9.PubMedCentralPubMedCrossRef

19.

Ho J, Moir S, Wang W, et al. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS. 2011;25:295–302.PubMedCentralPubMedCrossRef

20.

Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS. 2011;25:177–83.PubMedCrossRef

21.

Orlando G, Pariani E, Mazza F, et al. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS. 2010;24:2142–3.PubMedCrossRef

22.

Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6:e16496.PubMedCentralPubMedCrossRef

23.

Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. Am J Respir Crit Care Med. 2001;164:2120–6.PubMedCrossRef

24.

Durier C, Desaint C, Lucht F, et al. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. AIDS. 2013;27:87–93.PubMedCrossRef

25.

Nielsen AB, Nielsen HS, Nielsen L, Thybo S, Kronborg G. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. Vaccine. 2012;30:7067–71.PubMedCrossRef

26.

Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine. 2011;29:1359–63.PubMedCrossRef

27.

Ferguson M, Risi G, Davis M, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis. 2012;205:733–44.PubMedCrossRef

28.

Ikematsu H, Nagai H, Kawashima M, et al. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vaccin Immunother. 2012;8:260–6.PubMedCentralPubMedCrossRef

29.

Cooper CL. Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity. Curr Opin Infect Dis. 2012;25:26–35.PubMedCrossRef

30.

Asner S, Peci A, Marchand-Austin A, et al. Respiratory viral infections in institutions from late stage of the first and second waves of pandemic influenza A (H1N1) 2009, Ontario, Canada. Influenza Other Respir Viruses. 2012;6:e11–5.PubMedCrossRef

31.

Labrosse B, Tourdjman M, Porcher R, et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 influenza viruses using a pseudotype neutralization assay. PLoS One. 2010;5:e11036.PubMedCentralPubMedCrossRef

32.

Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir Viruses. 2013;7:872–86.PubMedCrossRef

33.

Villard O, Breit L, Cimon B, et al. Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies. Clin Vaccine Immunol. 2013;20:197–204.PubMedCentralPubMedCrossRef

34.

Dollard SC, Staras SA, Amin MM, Schmid DS, Cannon MJ. National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity. Clin Vaccine Immunol. 2011;18:1895–9.PubMedCentralPubMedCrossRef

35.

Fox JL, Hazell SL, Tobler LH, Busch MP. Immunoglobulin G avidity in differentiation between early and late antibody responses to West Nile virus. Clin Vaccine Immunol. 2006;13:33–6.PubMedCentralPubMedCrossRef

36.

Mercader S, Garcia P, Bellini WJ. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin Vaccine Immunol. 2012;19:1810–7.PubMedCentralPubMedCrossRef

37.

Park DW, Nam MH, Kim JY, et al. Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. Vaccine. 2007;25:4665–70.PubMedCrossRef

38.

Sanz-Moreno JC, Limia-Sanchez A, Garcia-Comas L, et al. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Vaccine. 2005;23:4921–5.PubMedCrossRef

39.

Hazell SL. Clinical utility of avidity assays. Expert Opin Med Diagn. 2007;1:511–9.PubMedCrossRef

40.

Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009;48:1402–12.PubMedCrossRef

41.

Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18:3040–9.PubMedCrossRef

42.

Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995;182:1727–37.PubMedCrossRef

43.

Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45:234–40.PubMedCrossRef

44.

Kelly D, Burt K, Missaghi B, et al. Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals. BMC Immunol. 2012;13:49.PubMedCentralPubMedCrossRef

45.

Calmy A, Bel M, Nguyen A, et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med. 2012;13:207–18.PubMed

Titel: High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine
verfasst von: Karen K. Yam
Erica Gipson
Marina Klein
Sharon Walmsley
David Haase
Scott Halperin
David Scheifele
Brian J. Ward
Curtis Cooper
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 6/2014
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-014-0054-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

SCIg vs IVIg: Let’s Give Patients the Choice!

Novel NFKB2 Mutation in Early-Onset CVID

Autoimmunity and Inflammation in X-linked Agammaglobulinemia

Clinical and Molecular Features of 38 Children with Chronic Granulomatous Disease in Mainland China

A Complement Factor B Mutation in a Large Kindred with Atypical Hemolytic Uremic Syndrome